Analyst Rating Update on Array BioPharma (ARRY)

Array BioPharma (ARRY) has an average broker rating of 1, which is interpreted as a Strong Buy, as rated by 8 equity analysts. Nonetheless, 8 analysts are positive on the stocks future and they recommend a Strong Buy on the stock. Ranking by Zacks Investment Research for Coach Inc is 2, which is also a Buy.

Array BioPharma (ARRY) : The highest level Array BioPharma (ARRY) is projected to reach is $13 for the short term and the lowest estimate is at $7. The consolidated price target from 6 rating analysts who initiate coverage on the stock is $8.5 and the possibility the share price can swing is $2.35.

For the current week, the company shares have a recommendation consensus of Buy.


Array BioPharma (NASDAQ:ARRY): During Wednesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $4.06 and $4.01 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $4.16. The buying momentum continued till the end and the stock did not give up its gains. It closed at $4.10, notching a gain of 0.49% for the day. The total traded volume was 1,365,921 . The stock had closed at $4.08 on the previous day.

Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs to treat patients afflicted with cancer. The Companys wholly owned clinical stage drugs include Filanesib in Phase II clinical trials, is indicated for Kinesin spindle protein (KSP), inhibitor for MM; ARRY-797 in Phase II clinical trials, indicated for p38 inhibitor for Lamin A/C-related dilated cardiomyopathy (LMNA-DCM); ARRY-502 in Phase II clinical trials, indicated for CRTh2 antagonist for asthma, and ARRY-614 in Phase I clinical trials, is indicated for p38/Tie2 dual inhibitor for myelodysplastic syndromes (MDS). In addition, the Company has 11 ongoing partner-funded clinical programs, including two MEK inhibitors, which are both in Phase III clinical trials, binimetinib with Novartis and selumetinib with AstraZeneca.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *